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Open access under CC BYMonocyte adhesion to the arterial endothelium and subsequent migration into the intima are central
events in the pathogenesis of atherosclerosis. Previous experimental models have shown that chemo-
kines can enhance monocyte–endothelial adhesion by activating monocyte integrins. Our study assesses
the role of chemokines IL-8, MCP-1 and GRO-a, together with their monocyte receptors CCR2 and CXCR2
in monocyte adhesion to human atherosclerotic plaques. In an adhesion assay, a suspension of monocytic
U937 cells was incubated with human atherosclerotic artery sections and the levels of endothelial adhe-
sion were quantiﬁed. Adhesion performed in the presence of a monoclonal antibody to a chemokine, che-
mokine receptor or of an isotype matched control immunoglobulin, shows that antibodies to all
chemokines tested, as well as their receptors, inhibit adhesion compared to the control immunoglobulins.
Immunohistochemistry demonstrated the expression of MCP-1, GRO-a and their receptors in the endo-
thelial cells and intima of all atherosclerotic lesions. These results suggest that all these chemokines and
their receptors can play a role in the adhesion of monocytes to human atherosclerotic plaques. Further-
more, they suggest that these chemokine interactions provide potential targets for the therapy of
atherosclerosis.
 2008 Elsevier Ltd.Open access under CC BY license.1. Introduction
The migration of monocytes into the intima gives rise to a mac-
rophage population that is central to atherosclerosis. It is clearly
important to identify accurately in the human disease the adhesion
mechanisms that allow monocyte trafﬁc into the arterial wall.
There is a possibility that species differences may exist, for exam-
ple our previous functional study on human tissues [1] failed to
conﬁrm a role for VCAM-1, an adhesion molecule implicated in ani-
mal models. In this study on human atherosclerosis we investigate
the roles of three chemokines and their receptors in inducing
monocyte adhesion.
Monocyte–endothelial contact through adhesion molecules can
be enhanced by chemokines, which can induce arrest of cells from
ﬂow, in addition to their chemotactic role [2,3]. Consequent activa-
tion of integrins can mediate tight static adhesion [4]. Adhesion re-
quires higher levels of receptor stimulation than chemotaxis [5].
MCP-1 (Monocyte chemoattractant protein-1, CCL2) acts via its
receptor CCR2. GRO-a (Growth related oncogene-a, CXCL1) and IL-
8 (Interleukin 8, CXCL8) share a common receptor CXCR2. MCP-1 isic Centre, Henriette Raphael
n SE1 1UL, UK.
n).
 license.amajormonocytechemotactic factor that is synthesized inmanycell
types. It is induced bymodiﬁed-LDL in endothelial cells [6], andmay
trigger ﬁrm adhesion of monocytes to vascular endothelium under
ﬂow [7], but not in all studies [8,9] It can stimulatemacrophage inﬁl-
tration into the arterialwall [10], but there is little information on its
level in theendothelium.Reductionof lesion size inMCP-1/ apoE/
micehas implicated it in the apoEgenedeletedmouse atherosclerosis
model [11]. CCR2 is a G-coupled receptor, through which MCP-1 in-
duces monocyte adhesion and chemotaxis. Sustained adhesion to
endotheliummayresult fromaprolongedactivationofMac-1 integrin
and binding to ICAM-1 [12]. Gene disruption experiments have impli-
cated it inmurine atherosclerosis [13].
GRO-a is induced by oxidised LDL [14] and laminar shear stress
[15] in endothelial cells. In mouse atherosclerosis it has a major
role in monocyte adhesion [9], but its involvement in the human
disease has not been reported. It induces monocyte adhesion to
modiﬁed-LDL stimulated endothelium [14]. In human umbilical
vein endothelial cells (HUVEC) it is induced by TNFa and binds
to surface heparan sulphate proteoglycans. This resulted in the
ﬁrm adhesion of monocytes under ﬂow conditions [8].
IL-8 is associated with acute inﬂammatory states through its
potent neutrophil chemotactic effects. It is induced by oxidised
LDL and low shear stress in endothelial cells [16], and has been de-
tected in the endothelium of human atherosclerotic plaques [17].
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to E-selectin expressing monolayers of vascular endothelium [18].
CXCR2 is the G-coupled receptor of both GRO-a and IL-8. Its
expression is proatherogenic as CXCR2 deﬁciency reduces the pro-
gression of advanced atherosclerosis in mice, and it may have a
role in retaining macrophages in the lesions [19]. Oxidised LDL
upregulates the expression of CXCR2 on the surface of human
monocytes, and of its mRNA [20]. Recently, the cytokine MIF (mac-
rophage migration inhibition factor) has been found to have a role
in leukocyte recruitment in atherosclerosis by signalling through
CXCR2 and CXCR4 [21]. CXCR1 also serves as a receptor for IL-8
and GRO-a on neutrophils, but the levels on human monocytes
and macrophages are low [22] and no functional information is
available on its role in these cells. It has not been investigated in
this study.
Previous investigation of the role of chemokines in a mouse ath-
erosclerosis model showed that KC, the mouse CXCL1, induced the
arrest of monocytes on atherosclerotic endothelium in vivo [9].
However, JE, the mouse CCL2, was ineffective. KC was operative
through activation of a4b1 integrin and its binding to endothelial
VCAM-1, but such a VCAM-1 dependent mechanismmay not apply
in man, as mentioned above [1].
The human disease can be investigated by the previously de-
vised ex vivo technique in which sections of human atherosclerotic
arteries are tested for adhesion with the U937 human monocytic
cell line [1]. We used this assay to investigate the effect of blocking
monocyte–endothelial adhesion by antibodies to chemokines and
their receptors. We have also conﬁrmed by immunohistochemistry
the expression of these molecules in the endothelium of athero-
sclerotic human carotid arteries.
2. Materials and methods
2.1. Human carotid endarterectomy specimens
Human carotid endarterectomy specimens were obtained
with ethical permission from male or female patients aged be-
tween 65 and 80 with a carotid stenosis of greater than 70%,
as demonstrated by digital subtraction angiography and duplex
ultrasonography. The investigation conformed with the princi-
ples outlined in the Declaration of Helsinki [23]. The arteries
used had advanced atherosclerotic lesions of grade III–V in Stary
classiﬁcation. The arteries were snap frozen and stored at
80 C. Cryostat sections from the stored specimens were cut
at 8 lm and placed on APES coated slides and dried for 2 h.
The slides were stored at 80 C.
2.2. Antibodies
Antibodies to MCP-1 (clone hmcp1, IgG2a, Serotec, Kidlington,
UK), GRO-a (clone 20326.1, IgG2b, Abcam, Cambridge, UK), IL-8
(clone 6217, IgG1, R&D Systems, Abingdon, UK), CCR2 (clone
48607.121, IgG2b, R&D Systems) and CXCR2 (clone 48311, IgG2a,
R&D Systems) were used for inhibition of cell adhesion. They
were compared with their isotype matched control immunoglob-
ulins UPC10 (IgG2a), MOPC141 (IgG2b) and MOPC21 (IgG1) (Sig-
ma–Aldrich, Gillingham, Dorset, UK) as the negative control.
UPC10 has irrelevant antibody activity against b2–6 linked fruc-
tosan (supplier’s datasheet). Previous work had shown that these
control immunoglobulins have little effect on adhesion them-
selves [1]. EBM11 (IgG1, CD68, Dako) was also used as a negative
control. All antibodies and immunoglobulins were added to the
cell suspension at 20 lg/ml immediately before addition to the
tissue sections. This concentration of antibody had been estab-
lished as optimal from previous titration experiments.2.3. Cell culture and tissue adhesion assay
U937 cells were cultured and the assay performed essentially as
previously described [1]. Brieﬂy, the cultured cells ﬁrst had the
medium pH corrected to neutrality, and then were stimulated with
10 ng/ml PMA for 16–24 h. Native U937 cells are at a promonocytic
stage of differentiation, and require stimulation with PMA to en-
able their development to a monocytic phenotype with expression
of CD14. These cells then have adhesive properties on arterial tis-
sue sections that are very similar to those of blood monocytes
[1]. They were then washed, antibodies were added, and 200 ll
of cell suspension was added to the slides, which were placed on
a horizontally rotating tray, and rotated at 60 rpm for 40 min at
37 C. The slides were then placed vertically in a slide staining rack
and rapidly dipped six times into a PBS bath to remove non-adher-
ent cells. They were ﬁxed with 4% paraformaldehyde (VWR, Lutter-
worth, UK) for 20 min. The endothelium was immunostained with
peroxidase conjugated rabbit anti-human von Willebrand Factor
(vWF) (Dako) 13 lg/ml for 30 min. They were washed twice, and
the reaction developed with hydrogen peroxide and diaminobenzi-
dine (DAB) (Sigma) for about 10 min. Slides were washed in water,
counterstained in Mayer’s haemalum (VWR) for 30 s, rinsed, and
differentiated for 10 s in acid alcohol (0.5% concentrated HCl in
70% ethanol/water). They were then dehydrated in three baths of
96% ethanol and two of xylene, 2 min in each, and mounted in
DPX (VWR). For each antibody assessed, three experiments with
quadruplicate slides were performed, each experiment with a dif-
ferent artery. Other adhesion experiments on the properties of con-
trol and irrelevant antibodies were done as triplicate assays.
Previous work [1] had shown that uninhibited adhesion to normal
artery was substantially less than to atherosclerotic plaque, so nor-
mal tissue was not investigated in this study.
2.4. Cell counting
Cells attached to an intact endothelial luminal surface were
counted. The counting was performed on an image analyser, and
the endothelial segment lengths were measured. Usually 12 seg-
ments of endothelium of mean length 170 lm were assessed per
slide. Adhesion was expressed as cell numbers/mm of endothe-
lium. Analysis was performed blind to slide conditions. Cells also
adhered to the cut surface of the intima (Fig. 1A), as previously re-
ported [1] but these were not quantitated.
2.5. Statistical analysis
Results are given as percentage of control adhesion ± standard
error. They were analysed by two-way analysis of variance (ANO-
VA, Prism, Graph Pad Prism Software, San Diego, CA). A p-value
of <0.05 was considered signiﬁcant.
2.6. Immunohistochemistry
Immunohistochemistry (reagents from Dako) was performed by
the avidin–biotin complex (ABC) technique to characterize the
arteries and to assess the expression of the chemokines and their
receptors. The arteries were ﬁrst blocked in normal rabbit serum
1/10. Reagents were made in PBS, and stages were separated by
two 5 min washes, except after this blocking. Primary antibodies
were EBM11 (4.50 lg/ml) for CD68/ macrophages and HHF35
(1 lg/ml) for smooth muscle cell actin, in 90 min incubations. For
chemokine/receptor staining (6 arteries), antibodies were used at
20 lg/ml. The secondary antibody was biotinylated F(ab0)2 rabbit
anti-mouse immunoglobulin (2.1 lg/ml), and was incubated for
30 min. The avidin–biotin–peroxidase complex was then applied
Fig. 1. U937 cell–atherosclerotic plaque adhesion assay, performed as described in
Section 2. The endothelium is stained with an anti-von Willebrand factor antibody.
(A) Uninhibited adhesion with control mouse immunoglobulin 20 lg/ml. U937 cells
are adhering to the surface of the endothelium (arrows), and to the cut face of the
intima. (B) U937 adhesion is inhibited by the same concentration of mouse anti-
GROa antibody. Representative example of 12 experiments, original magniﬁcation
630.
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above.
2.7. Flow cytometry
U937 cells were stimulated with PMA as described, washed, and
incubated at 2.4  106 cells/ml with 20 lg/ml of the CCR2 and
CXCR2 antibodies for 60 min, then washed twice and incubated
with ﬂuorescein labelled F(ab0)2 rabbit anti-mouse immunoglobu-
lin (Dako) 20 lg/ml for 30 min. The negative primary antibody
control was isotype matched non-immunemouse immunoglobulin
(Sigma). The cells were washed twice and read in an EPICS XL ﬂow
cytometer (Beckman-Coulter, High Wycombe, UK).Fig. 2. Inhibition of U937 cell–plaque endothelium adhesion by antibodies to
chemokines and their receptors. The assays were performed as described in Section
2: each graph shows adhesion in isotype matched control immunoglobulin 20 lg/
ml compared to adhesion with antibody 20 lg/ml to the antigen indicated. The
mean ± SE of U937 cell adhesion per length of endothelium in three quadruplicate
experiments is shown. All antibodies cause highly signiﬁcant inhibition of adhesion,
***p < 0.001. (A) Anti-MCP-1; (B) anti-GROa; (C) anti-IL-8; (D) anti-CCR-2; (E) anti-
CXCR-2.3. Results
3.1. Speciﬁc inhibition of U937 cell adhesion to atherosclerotic human
artery endothelium by antibodies to chemokines
3.1.1. MCP-1
U937 cells bound to the endothelial cells of the sections of ath-
erosclerotic plaques, as previously described [1] (Fig. 1A), and che-
mokine antibodies inhibited this adhesion (Fig. 1B). The effect of
monoclonal antibody against MCP-1 was assessed by comparison
with the control immunoglobulin UPC10. It was shown that
MCP-1 blockage in the three experiments performed on three dif-
ferent tissues leads to endothelial adhesion of 34.6 ± 3.5% of the le-
vel of the control (p < 0.001). The results are represented in Fig. 2A.
The control UPC10 immunoglobulin itself gave a mean of 88.0% of
control adhesion (not signiﬁcantly different, NS) compared to tis-
sue culture medium in ﬁve experiments. Similarly EBM11, an anti-
body against the monocyte/macrophage intracellular antigen,
CD68, did not inhibit adhesion either to the endothelium (104%
Fig. 3. Immunohistochemistry of chemokines and their receptors in atherosclerotic
plaque intima. The avidin–biotin complex method was used as described in Section
2, with 20 lg/ml of primary antibody. All chemokines and receptors assayed show
strong expression in the surface endothelial cells and lesser reactions in scattered
cells within the intima. (A) MCP-1; (B) GROa; (C) CCR-2; (D) CXCR2. Representative
examples of 6 arteries shown, original magniﬁcation 630.
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experiments).
3.1.2. GRO-a
Three adhesion assays assessing the effect of monoclonal anti-
body against GRO-a showed an inhibition of monocyte adhesion
to 35.6 ± 5.2% of control (p < 0.001). Comparison was made with
the control immunoglobulin MOPC141. The results are shown in
Fig. 2B, and a histological image in Fig. 1B. MOPC141 itself gave
104% (NS) of control adhesion compared to tissue culture medium
(triplicate experiment).
3.1.3. IL-8
IL-8 blockage in the three experiments performed on different
tissues lead to adhesion at a level of 37.2 ± 9.6% of the control
(p < 0.001). Comparison was made with the control immunoglobu-
lin MOPC21. The results are represented in Fig. 2C. MOPC21 gave
88.4% of control adhesion (NS) compared to tissue culture medium
in eight experiments.
3.2. Speciﬁc inhibition of U937 cell adhesion to human atherosclerotic
plaque endothelium by antibodies to chemokine receptors
3.2.1. CCR2
Three adhesion assays assessing the effect of monoclonal anti-
body against CCR2 showed an inhibition of monocyte adhesion
to 48.6 ± 4.8% of the control with MOPC141 (p < 0.001). The results
are shown in Fig. 2D.
3.2.2. CXCR2
Similarly three assays with an antibody against CXCR2 showed
an inhibition of monocyte adhesion to 58.4 ± 8.7% of the control
with UPC10 (p < 0.001). The results are shown in Fig. 2E.
3.3. Expression of chemokines and their receptors in atherosclerotic
human arteries
3.3.1. MCP-1 and CCR2
Immunohistochemistry shows the presence of both MCP-1 and
its receptor CCR2 in the endothelial as well as the intimal cells of
advanced atherosclerotic lesions in human carotid arteries ( Fig.
3A and C). The expression of MCP-1 is greater in the endothelium
overlying atheromatous lesions than in the intima beneath, and in
parts is maximal on the apical surface of the endothelium. These
ﬁndings were consistent in all the atherosclerotic carotid arteries
examined.
3.3.2. GRO-a and CXCR2
GRO-a and its receptor CXCR2 are also expressed in both endo-
thelial and intimal cells of advanced human atherosclerotic lesions
(Fig. 3B and D). As with MCP-1 and its receptor, the staining is con-
sistently stronger in the endothelium overlying atherosclerotic pla-
ques compared to the connective tissue of their intima. The pattern
of CXCR2 expression suggests staining of the apical surface of the
endothelium.
3.4. Validation of U937 cells as a chemokine receptor expressing
monocyte cell model
3.4.1. CCR2 and CXCR2 expression in U937 cells
Flow cytometry demonstrated that CXCR2 (Fig. 4A) and CCR2
(not shown) were well expressed on the cell membrane of the
PMA stimulated U937 cells used in this study (2 similar experi-
ments). Furthermore, permeabilisation of the cells considerably in-
creased antibody reactivity (Fig. 4B), but with some elevation in
background signal.4. Discussion
This study has focused on the ability of chemokines to enhance
monocyte–endothelial adhesion in human atherosclerosis. This
mechanism is likely to be complementary to their better known
chemotactic activity in promoting cell migration into the arterial
wall. Our results, of effective blockage of monocyte adhesion to
atherosclerotic endothelium by both antibodies to chemokines
and to their receptors, provide the ﬁrst functional evidence for a
role of chemokines in inducing monocyte adhesion in human ath-
erosclerosis. These ﬁndings are similar to previous studies in ani-
mal models. Strong inhibition of adhesion with antibodies to
MCP-1, GROa and IL-8 in this assay suggests that all these chemo-
kines have a role in the adhesion of monocytes to the endothelium
Fig. 4. Expression of CXCR-2 in PMA stimulated U937 cells. The cells were stained
by a two antibody technique as described in Section 2. Histogram: X -axis,
ﬂuorescence intensity; Y-axis, number of cells. Grey envelope, anti CXCR2; black
ﬁlled graph, control mouse immunoglobulin UPC10. (A) Surface expression (non-
permeabilised); (B) permeabilised cells. CXCR2 is expressed on the U937 cell
membrane, and the reaction is enhanced by permeabilisation. One of two similar
experiments.
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the substantial evidence for its involvement in mouse atheroscle-
rosis [11], but with a possible greater role in monocyte arrest.
The ﬁndings with GRO-a support and extend the previous evidence
for the importance of this cell–surface bound chemokine in induc-
ing monocyte adhesion to mouse atherosclerotic endothelium and
to stimulated HUVEC [8,9]. Our ﬁnding of a role for IL-8 in the
monocyte–endothelial adhesion of atherosclerosis is novel, but is
consistent with related ﬁndings [18,24]. With the receptors, the re-
sults in man with CCR2 parallel its involvement in the mouse [13],
as do those for CXCR2 [25].
It is likely that signalling from the chemokines and receptors
studied is operating via the activation of b2 integrins. Previous work
with this assay showed amajor role for these integrins in permitting
monocyte–endothelial adhesion in human atherosclerosis [1], but
equivocal evidence for b1involvement (unpublished data).
The chemokine receptors CCR2 and CXCR2 were expressed in
the arterial endothelial cells of human atherosclerosis, in addition
to their expected expression in the U937 cells, which we have con-
ﬁrmed. These receptors have been noted previously on human
endothelial cells [26], and may mediate chemotactic responses in-
volved in the repair of a damaged endothelium. As the U937 cells
used in the assay are stimulated with PMA, they may express che-
mokines, and if so, it is possible that they might interact with the
receptors on the atherosclerotic endothelium. Whether such an
interaction could contribute to adhesion is not clear. However,
such considerations emphasise that PMA stimulated U937 cells
model accurately the interactions of activated monocytes in vivo.
This form of adhesion assay with tissue sections was ﬁrst used
in seminal studies by Stamper and Woodruff [27] to demonstrate
the interaction of circulating lymphocytes with high endothelial
venules in lymph nodes. It enables the efﬁcient use ex vivo of
scarce human material, and permits controlled replicated adhesion
experiments on the human tissues. Here transverse histologicalsections of human arteries provide the substrate for adhesion,
and allow the comparison of near identical samples in replicates
with statistical analysis. As a consequence of the use of tissue sec-
tions, the endothelial cells are transected. Therefore, the mode of
access of the test U937 cells to the artery wall allows contact with
the normally unavailable intracellular contents on the cut face. It is
possible that exposed molecules might mediate adhesion interac-
tions not present in vivo, but there is no evidence that this is the
case. Furthermore, it is encouraging that the antibody EBM11,
against the highly expressed CD68 intracellular antigen of plentiful
plaque macrophages, was without effect on adhesion. This
suggests that antibody binding to a molecule irrelevant to physio-
logical interactions is without effect. In addition, in this study,
non-speciﬁc effects of immunoglobulins have been controlled by
making comparison with isotype matched non-immune mouse
immunoglobulins in all experiments. These immunoglobulins
themselves are demonstrated to have no signiﬁcant effect on
adhesion.
From these observations alone it is difﬁcult to determine
whether the adhesion ligands operative in the assay are on the api-
cal endothelial surface. However, it is established that MCP-1 [28],
GROa [14] and IL-8 are synthesized by endothelial cells, that IL-8
can be transcytosed from the abluminal to the luminal surface
[29], and that all chemokines bind to the glycosoaminoglycans of
the glycocalyx on the apical surface [30], althoughMCP-1 may bind
less than GRO-a [8]. Interestingly, the MCP-1 immunohistochemis-
try gives some evidence of endothelial luminal surface staining
(Fig. 3A). Therefore, it is very likely that the chemokines studied
are presented at the endothelial surface and are capable of enhanc-
ing adhesion in vivo.
In the studies on monocyte adhesion done in this laboratory
by this technique, antibodies to several monocyte receptors,
(e.g. previously b2 integrins and CD14; in this report CCR2 and
CXCR2), have strongly inhibited the monocyte–endothelial
interaction [1]. Antibodies to endothelial adhesion molecules
and chemokines (previously P-selectin, ICAM-1; here MCP-1,
GROa and IL-8) have acted similarly. This inhibition is not due
merely to the presence of antibody on the surface of the cells,
as it was shown previously that an antibody to MHC-II, which
is expressed strongly on U937 cells, was without inhibitory ef-
fect [1].
It is interesting that blocking of so many of the molecules in-
volved in ligand–receptor adhesion interactions can inhibit cellu-
lar adhesion. As many molecules are involved, it might be
expected that blocking of any one pair would have little effect.
The interaction between the various pairs must therefore be
complex: sequential operation of ligands and signalling interac-
tions are likely to be involved. Further, as the adhesion mecha-
nism involves multimolecular complexes at focal adhesion
contacts, and possibly membrane microdomains such as lipid
rafts [31], it is likely that highly organised macromolecular
structures are involved, as has been found in the T lympho-
cyte-antigen presenting cell interaction [32]. These complexes
may include chemokine receptors [33]. It seems possible that
the molecules are cooperating to produce adhesion in a highly
integrated manner, and it may be that ligation or blocking of
one can affect the operation of the adhesion mechanism as a
whole. Ultrastructural studies could be of interest.
The critical dependence of atherogenesis on monocyte–endo-
thelial adhesion encourages further research on the role of che-
mokines in its mechanism. The possibility of the use of speciﬁc
chemokine inhibitors as therapeutic agents in man is supported
by this study. Anti-chemokine therapy is effective in animal
models [34], and a wide range of established anti-atherosclerotic
agents, including aspirin and statins, are already known to inhi-
bit the expression of MCP-1 [35] or its receptor CCR-2 [36].
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